We provide you with 20 years of free, institutional-grade data for SAVA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SAVA. Explore the full financial landscape of SAVA stock.
Total insider purchase within 3 month on this page: $563,106
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Cook Robert Christopher | Open Market Purchase | 13,725 | $2.91 | 2025-10-02 | |
| Barry Richard | Open Market Purchase | 7,172 | $2.28 | 2025-09-23 | |
| Barry Richard | Open Market Purchase | 237,941 | $2.13 | 2025-09-22 | |
| Schoen Eric | Sale | -2,000 | $3.82 | $7,640 | 2024-12-03 |
| Schoen Eric | Sale | -59,800 | $3.86 | $230,828 | 2024-12-03 |
| Schoen Eric | Derivatives Exercise | 50,000 | 2024-12-03 | ||
| Kupiec James William | Sale | -4,000 | $3.87 | $15,480 | 2024-12-03 |
| ROBERTSON SANFORD | Grant, award...etc | 72,000 | 2024-04-30 | ||
| ROBERTSON SANFORD | Derivatives Exercise | 23,000 | 2024-04-30 | ||
| ROBERTSON SANFORD | Grant, award...etc | 354,740 | 2024-04-30 | ||
| Barry Richard | Derivatives Exercise | 58,695 | 2024-04-25 | ||
| Barry Richard | Grant, award...etc | 117,390 | 2024-04-25 | ||
| Kupiec James William | Derivatives Exercise | 500 | 2024-04-22 | ||
| Kupiec James William | Grant, award...etc | 1,000 | 2024-04-22 | ||
| Schoen Eric | Grant, award...etc | 800 | 2024-04-17 | ||
| Schoen Eric | Derivatives Exercise | 500 | 2024-04-17 | ||
| Schoen Eric | Grant, award...etc | 7,920 | 2024-04-17 | ||
| ROBERTSON SANFORD | Open Market Purchase | 30,000 | $17.45 | 2023-08-24 | |
| Barry Richard | Open Market Purchase | 18,477 | $16.8 | 2023-08-23 | |
| SCANNON PATRICK J MD PHD | Derivatives Exercise | 1,000 | 2023-06-12 | ||
| BARBIER REMI | Sale | -9,545 | $25.25 | $241,011 | 2023-05-25 |
| BARBIER REMI | Derivatives Exercise | 14,285 | 2023-05-25 | ||
| BARBIER REMI | Sale | -47,723 | $25.25 | $1,205,006 | 2023-05-25 |
| BARBIER REMI | Derivatives Exercise | 71,428 | 2023-05-25 | ||
| ROBERTSON SANFORD | Derivatives Exercise | 9,284 | 2023-05-10 | ||
| GUSSIN ROBERT Z | Sale | 7,077 | $23.34 | 2023-05-02 | |
| GUSSIN ROBERT Z | Derivatives Exercise | 9,284 | 2023-05-02 | ||
| Barry Richard | Open Market Purchase | 88,841 | $26.13 | 2023-03-08 | |
| O DONNELL MICHAEL J | Sale | -5,139 | $25.2 | $129,503 | 2023-03-08 |
| O DONNELL MICHAEL J | Derivatives Exercise | 7,142 | 2023-03-08 | ||
| FRIEDMANN NADAV | Derivatives Exercise | 0 | 2022-10-03 | ||
| ROBERTSON SANFORD | Derivatives Exercise | 0 | 2022-09-12 | ||
| Barry Richard | Open Market Purchase | 36,159 | $23.79 | 2022-08-25 | |
| Kupiec James William | Open Market Purchase | 2,500 | $24.44 | 2022-08-24 | |
| Schoen Eric | Open Market Purchase | 2,500 | $19.95 | 2022-08-16 | |
| ROBERTSON SANFORD | Open Market Purchase | 100,000 | $20.69 | 2022-08-16 | |
| BARBIER REMI | Sale | -54,720 | $27.93 | $1,528,330 | 2022-06-07 |
| BARBIER REMI | Derivatives Exercise | 0 | 2022-06-07 | ||
| FRIEDMANN NADAV | Sale | -24,569 | $26.66 | $655,010 | 2022-05-31 |
| FRIEDMANN NADAV | Derivatives Exercise | 0 | 2022-05-31 | ||
| BARBIER REMI | Derivatives Exercise | 0 | 2022-04-25 | ||
| GUSSIN ROBERT Z | Sale | -4,024 | $39.98 | $160,880 | 2022-03-29 |
| GUSSIN ROBERT Z | Derivatives Exercise | 0 | 2022-03-29 | ||
| ROBERTSON SANFORD | Derivatives Exercise | 0 | 2022-03-28 |
The information provided in this report about SAVA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Cassava Sciences, Inc(NASDAQ:SAVA) 
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-b...
Website: https://www.cassavasciences.com/
Founded: 1998
Full Time Employees: 9
CEO: Remi Barbier
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends